Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Morpholine SCHEMBL10426239 | 0.92 | MEN1 (0.52) | MEN1KMT2AKDM4EGAACYP2C9 | |
| Oxazolidine SCHEMBL5786262 | 0.85 | MEN1 (0.38) | MEN1KMT2AKDM4EGAACYP2C9 | |
| SCHEMBL7534613 | 0.85 | MEN1 (0.57) | MEN1KMT2AKDM4EGAACYP2C9 | |
| SCHEMBL11557802 | 0.83 | MEN1 (0.61) | MEN1KMT2AKDM4EGAACYP2C9 | |
| SCHEMBL916800 | 0.83 | — | — | |
| SCHEMBL733311 | 0.83 | — | — | |
| SCHEMBL25183744 | 0.80 | — | — | |
| Cyclopropane SCHEMBL11497951 | 0.80 | — | — | |
| Hydrochloric Acid SCHEMBL693656 | 0.80 | — | — | |
| Ammonia Solution, Strong SCHEMBL16292425 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1981859-B1 | PREPARATION OF DELMOPINOL | SINCLAIR PHARMACEUTICALS LTD (GB) | 2012-10-31 | — | — | EP | disclosed |
| US-8093398-B2 | Preparation of delmopinol | Sinclair Pharmaceticals Limited (GB) | 2012-01-10 | — | — | US | disclosed |
| US-20110082301-A1 | Preparation of Delmopinol | COMELY ALEXANDER | 2011-04-07 | — | — | US | disclosed |
| US-7893258-B2 | Preparation of delmopinol | SINCLAIR PHARMACEUTICALS LIMITED (GB) | 2011-02-22 | — | — | US | disclosed |
| US-20090036677-A1 | Preparation of Delmopinol | MAELOR LABORATORIES LIMITED (GB) | 2009-02-05 | — | — | US | disclosed |
| EP-1981859-A2 | PREPARATION OF DELMOPINOL | Sinclair Pharmaceuticals Limited (GB) | 2008-10-22 | — | — | EP | disclosed |
| WO-2007091009-A2 | PREPARATION OF DELMOPINOL | SINCLAIR PHARMACEUTICALS LIMITED (GB) | 2007-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110082301-A1 | Preparation of Delmopinol | CBR3, AVPR2, C1S | MEN1 144/4885KMT2A 4428/4885KDM4E 4564/4885 |
| US-20090036677-A1 | Preparation of Delmopinol | AVPR2, CBR3, C1S | MEN1 124/4885KMT2A 4496/4885KDM4E 4619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.